The ozone paradox: ozone is a strong oxidant as well as a medical drug
Bocci V, Borrelli E, Travagli V, et al. Medicinal Research Reviews, 2009.
- Study type
- Narrative review
- People studied
- No participants of its own (narrative review)
- Published
- 2009, Medicinal Research Reviews
- Identifiers
- PMID 19260079, DOI 10.1002/med.20150
What the authors reported
Explains that prolonged ozone inhalation is toxic to the lungs and body, whereas a single, precisely calibrated ozone dose dissolved in blood ex vivo triggers antioxidant and biochemical responses in blood cells and endothelium that the authors describe as therapeutically useful without toxicity in selected diseases.
What limits this result
Narrative review by long-time ozone-therapy proponents that synthesizes prior mechanistic work rather than presenting new controlled data.
How ozone acts on blood and cells, how blood filters work, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Autoimmune Conditions: Rheumatoid Arthritis, MS, Lupus and the Evidence
What the ACR rheumatoid arthritis guideline and small ozone autohemotherapy studies actually show about EBO2 (also called EBOO) for autoimmune disease.
EBO2 (EBOO) for Longevity and Anti-Aging: The Oxidative Preconditioning Idea
A sourced look at EBO2 (EBOO) for longevity: the oxidative preconditioning idea behind the marketing, and why no study yet ties it to lifespan.
The History of EBO2 (EBOO): From Bocci's Lab to Today's Wellness Clinics
How EBO2 (EBOO) developed from 19th-century ozone chemistry through Bocci's lab in Siena to today's US wellness clinics, with dates as documented in sources.
What Is EBO2 (EBOO) Therapy? Procedure, Evidence, Cost, and Safety
A neutral, sourced explainer of EBO2 (also called EBOO): how the procedure works, what the research shows, typical cost, and the FDA's position.